News > Longevity 2020From science fiction to FDA submission: ectopic organoids & the commercialization of regenerative medicine From science fiction to FDA submission: ectopic organoids & the commercialization of regenerative medicine
Author:
Phil Newman | Published on:
April 30, 2020 | Last updated:
May 10, 2022Michael Hufford
Co-Founder and CEO, LyGenesis
From science fiction to FDA submission: ectopic organoids & the commercialization of regenerative medicine